Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.80 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | ESR1 | P03372 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8759387 | 0.89 | ALDH1A1 (1.00) | ALDH1A1KDM4EMAPTNPSR1SMN1; SMN2 | |
| SCHEMBL10953409 | 0.89 | ALDH1A1 (0.66) | ALDH1A1KDM4EMAPTNPSR1SMN1; SMN2 | |
| SCHEMBL812682 | 0.79 | PKM (0.79) | ALDH1A1SMN1; SMN2PKMESR1KMT2A | |
| SCHEMBL3581609 | 0.79 | ALDH1A1 (0.53) | ALDH1A1KDM4EMAPTNPSR1SMN1; SMN2 | |
| SCHEMBL14247955 | 0.77 | MAPT (0.53) | ALDH1A1KDM4EMAPTNPSR1SMN1; SMN2 | |
| SCHEMBL5138358 | 0.77 | ALDH1A1 (0.58) | ALDH1A1KDM4EMAPTNPSR1SMN1; SMN2 | |
| SCHEMBL294183 | 0.76 | ALDH1A1 (0.51) | ALDH1A1KDM4EMAPTNPSR1SMN1; SMN2 | |
| SCHEMBL1728668 | 0.76 | ALDH1A1 (0.50) | ALDH1A1KDM4EMAPTNPSR1SMN1; SMN2 | |
| SCHEMBL2120039 | 0.75 | ALDH1A1 (0.56) | ALDH1A1KDM4EMAPTNPSR1KMT2A | |
| SCHEMBL14058258 | 0.75 | PKM (0.51) | ALDH1A1KDM4EMAPTNPSR1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263046-B2 | 4-methoxy-N-phenyl-N-[2-(pyridin-2-yl)ethyl]benz(enesulfon)amide and a second cooling agent, such as menthol or a derivative; similar cooling intensity to N-ethyl p-menthanecarboxamide (WS-3); ingestible or topical | GIVAUDAN S.A. (CH) | 2012-09-11 | — | — | US | disclosed |
| EP-1940791-B1 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2009-09-16 | — | — | EP | disclosed |
| US-20080253974-A1 | 4-methoxy-N-phenyl-N-[2-(pyridin-2-yl)ethyl]benz(enesulfon)amide and a second cooling agent, such as menthol or a derivative; similar cooling intensity to N-ethyl p-menthanecarboxamide (WS-3); ingestible or topical | GIVAUDAN S.A. (CH) | 2008-10-16 | — | — | US | disclosed |
| EP-1940791-A1 | ORGANIC COMPOUNDS | Givaudan SA (CH) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007048265-A1 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080253974-A1 | 4-methoxy-N-phenyl-N-[2-(pyridin-2-yl)ethyl]benz(enesulfon)amide and a second cooling agent, such as menthol or a derivative; similar cooling intensity to N-ethyl p-menthanecarboxamide (WS-3); ingestible or topical | CBR3, TRPM6, TRPV3 | ALDH1A1 3460/4885KDM4E 712/4885MAPT 3344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.